Nickel(II)-Methyl Pyridine Polymerization Catalysts
Organometallics, Vol. 26, No. 9, 2007 2361
C6D6, 25 °C): δ 8.11 (s, 1H, 33-H), 7.83 and 7.75 (m each, 2H
salicylaldimines, condensation of terphenylamine 4a (518 mg, 1
3
each, 29-, 30-, 36-, and 37-H), 7.54 (s, 1H, 7-H), 7.52 (d, JHH
)
mmol) with 5-nitrosalicylaldehyde (167 mg, 1 mmol) in 15 mL of
1
8.0 Hz, 2H, 10- and 12-H), 7.35 (m, 2H, o-H pyridine), 7.25 (s,
methanol gave salicylaldimine 12 (500 mg, 0.75 mmol, 75%). H
3
4H, 15-, 19-, 21-, and 25-H), 7.23 (t, JHH ) 8.0 Hz, 1H, 11-H),
NMR (399.8 MHz, CDCl3, 25 °C): δ 12.79 (s, 1H, OH), 8.12 (dd,
7.16 (m, 5H, 4-, 28-, 31-, 35-, and 38-H), 6.77 (dd, 3JHH ) 8.0 Hz
3JHH ) 9.2 Hz, JHH ) 2.8 Hz, 1H, 4-H), 8.06 (s, 1H, 7-H), 7.89
4
4
4
and JHH ) 2.0 Hz, 1H, 6-H), 6.39 (vt, JHH ) 8.0 Hz, 1H, 5-H),
(d, JHH ) 2.8 1H, 6-H), 7.87 (s, 4H, 15-, 19-, 21-, and 25-H),
6.16 (m, 1H, p-H pyridine), 5.59 (m, 2H, m-H pyridine), 3.86 (s,
6H, 17- and 23-OCH3), 3.70 (s, 12H, 16-, 18-, 22-, and 24-OCH3),
-0.76 (s, 3H, Ni-CH3). 13C{1H} NMR (100.5 MHz, C6D6, 25
°C): δ168.3 (CH, C7), 165.5 (Cq, C2), 154.0 (Cq, C16, C18, C22,
and C24), 150.8 (Cq, C17 and C23), 150.5 (CH, o-C pyridine),
139.0 and 136.4 (Cq each, C9, C13, C14, C20), 136.9 (CH, C4),
136.8 (Cq, C26), 134.9 (CH, p-C pyridine), 133.7 (CH, C6), 131.9
and 131.0 (Cq each, C27, C32, C34, and C39), 130.7 (Cq, C3),
129.8 (CH, C10 and C12), 128.7 and 128.5 (CH each, C28, C31,
C35, and C38), 126.3 (CH, C11), 125.5 (Cq, C33), 125.2 and 124.9
(CH each, C29, C30, C36, C37), 122.1 (CH, m-C pyridine), 120.7
(Cq, C1), 113.4 (CH, C5), 109.4 (CH, C15, C19, C21, and C25),
60.7 (CH3, 17- and 23-OCH3), 56.4 (CH3, 16-, 18-, 22-, and 24-
OCH3), -8.7 (CH3, Ni-CH3), C8 not detected. Anal. Calcd for
C45H38N2O7Ni (857.62 g mol-1): C, 71.43; H, 5.41; N, 3.27.
Found: C, 71.00; H, 5.72; N, 2.84.
1.83 (s, 2H, 17- and 23-H), 7.58 (m, 3H, 10-12-H), 7.02 (d, 3JHH
) 9.2 Hz, 1H, 5-H). 13C{1H} NMR (100.5 MHz, CDCl3, 25 °C):
δ 168.4 (CH, C7), 166.0 (Cq, C2), 144.5 (Cq, C8), 140.4 and 132.1
2
(Cq each, C9, C13, C14, and C20), 140.1 (Cq, C5), 132.1 (q, JCF
) 34 Hz, C16, C18, C22, and C24), 131.5 (CH, C10 and C12),
129.8 (CH, C15, C19, C21, and C25), 129.3 (CH, C4), 128.3 (CH,
1
C6), 127.5 (CH, C11), 123.0 (q, JCF ) 272 Hz, 4 × CF3), 121.4
(m, CH, C17 and C23), 118.4 (CH, C3), 116.7 (Cq, C1). (b)
Preparation of Complex 10a-pyr. To a mixture of [(tmeda)Ni-
(CH3)2] (100 mg, 0.49 mmol) and salicalyldimine 12 (326 mg, 0.49
mmol) in a 25 mL Schlenk flask was added a solution of 0.5 mL
of pyridine in diethyl ether (10 mL) at -30 °C under stirring. The
temperature was slowly raised to 0 °C, while the color changed to
orange-red. After 2 h at 0 °C, the solvent was removed under
vacuum (10-3 mbar), and the residue was washed with small
amounts of cold pentane to leave complex 10a-pyr as an orange
1
powder (213 mg, 0.26 mmol, 53%). H NMR (399.8 MHz, CD2-
Cl2, 25 °C): δ 8.33 (m br, 2H, o-H pyr), 8.28 (s, 4H, 15-, 19-, 21-,
3
and 25-H), 8.02 (s, 2H, 17- and 23-H), 7.93 (dd, JHH ) 9.2 Hz,
4
4JHH ) 2.8 Hz, 1H, 4-H), 7.88 (d, JHH ) 2.8 Hz, 1H, 6-H), 7.68
(s br, 2H, 7-H and p-H pyr), 7.55 (m, 3H, 10-12-H), 7.20 (m br,
3
2H m-H pyr), 6.33 (d, JHH ) 9.2 Hz, 3-H), -0.98 (s, 3H, Ni-
CH3). 13C{1H} NMR (100.5 MHz, CD2Cl2, 25 °C): δ 171.2 (Cq,
C2), 168.2 (CH, C7), 150.9 (CH br, o-C pyr), 149.6 (Cq, C8), 141.0
and 133.0 (Cq each, C9, C13, C14, and C20), 137.1 (CH br, p-C
pyr), 135.5 (Cq, C5), 131.8 (CH, C6), 131.7 (q, 2JCF ) 33 Hz, C16,
C18, C22, and C24), 131.1 (CH, C10 and C12), 130.6 (CH br,
C15, C19, C21, and C25), 128.8 (CH, C4) 127.5 (CH, C11), 123.5
(q, 1JCF ) 272 Hz, 4 × CF3), 123.2 (CH br, m-C pyr), 122.6 (CH,
C3), 121.5 (m, CH, C17 and C23), 117.7 (Cq, C1), -7.3 (CH3,
Ni-CH3).
Complex 1a-pyr. Following the general procedure method A,
113 mg (186 µmol, 93%) of compound 1-pyr was obtained from
[(tmeda)NiMe2] (40.8 mg, 200 µmol), 2-anthracen-9-yl-6-[(2,6-di-
isopropylphenylimino)-methyl]-phenol (91.4 mg, 200 µmol), and
pyridine (240 mg, 3.04 mmol) in benzene as an orange-red powder.
1H NMR (399.8 MHz, C6D6, 25 °C): δ 8.16 (s, 1H, 21-H), 8.06
and 7.75 (d each, JHH ) 8.8 Hz, 2H each, 16-, 19-, 23- and 26-H),
7.79 (s, 1H, 7-H), 7.75 (m, 2H, o-H pyridine), 7.36 and 7.18 (d
3
each, JHH ) 7.2 Hz, each, 1H each, 4- and 6-H), 7.11 and 6.94
(m:t, JHH ) 7.4 Hz, 5:2H, 10-12-, 17-, 18-, 24-, and 25-H), 6.67
3
(vt, JHH ) 7.2 Hz, 1H, 5-H), 6.27 (vt br, JHH ) 7.2 Hz, 1H, p-H
pyridine), 5.61 (vt br, JHH ) 6.2 Hz, 2H, m-H pyridine), 4.26 (m,
i
3
2H, 2 × Pr), 1.44 and 1.12 (d each, JHH ) 7.2 Hz each, 6:6H, 2
× Pr), -0.80 (s, 3H, Ni-CH3). 13C{1H} NMR (100.5 MHz, C6D6,
i
25 °C): δ 166.5 (CH, C7), 166.2 (Cq, C2), 151.5 (CH, o-C
pyridine), 150.2 (Cq, C8), 141.2 (Cq, C9 and C13), 137.1 (CH each,
C4), 135.0 (p-C pyridine), 134.1 (CH, C6), 132.0 and 131.3 (Cq
each, C15, C20, C22, and C27), 131.0 (Cq, C3 and C14), 128.5
and 128.1 (CH each, C16, C19, C23, and C26), 126.5 (CH, C10
and C12), 125.6 (CH, C21), 123.6 (CH, C11), 122.2 (CH, m-C
Synthesis of Complex 11a-pyr. (a) Preparation of Salicylal-
dehyde 13. Following the general procedure for the synthesis of
salicylaldimines, condensation of terphenylamine 4a (518 mg, 1
mmol) with 3-(tert-butyl)alicylaldehyde (178 mg, 1 mmol) in 15
mL of methanol gave salicylaldimine 13 (589 mg, 0.87 mmol, 87%).
1H NMR (399.8 MHz, C6D6, 25 °C): δ 12.61 (s, 1H, OH), 7.68
(s, 4H, 15-, 19-, 21-, and 25-H), 7.56 (s, 2H, 17- and 23-H), 7.12
i
pyridine), 120.5 (Cq, C1), 113.7 (CH, C5), 28.5 (CH, 2 × Pr),
i
28.5 and 25.0 (CH3 each, 2 × Pr), -7.3 (CH3, Ni-CH3). Anal.
Calcd for C39H38N2ONi (609.43 g mol-1): C, 76.86; H, 6.28; N,
4.60. Found: C, 76.40; H, 6.71; N, 4.08.
3
4
(dd, JHH ) 7.6 Hz, JHH ) 1.6 Hz, 1H, 4-H), 6.93 (m, 4H, 7-H
and 10-12-H), 6.38 (vt, JHH ) 7.6 Hz, 5-H), 6.22 (dd, 3JHH ) 7.6
4
t
Hz, JHH ) 1.6 Hz, 1H, 6-H), 1.49 (s, 9H, Bu). 13C {1H} NMR
(100.5 MHz, C6D6, 25 °C): δ 170.9 (CH, C7), 160.9 (Cq, C2),
146.1 (Cq, C8), 141.2 and 132.1 (Cq each, C9, C13, C14, and C20),
138.2 (Cq, C3), 132.0 (q, 2JCF ) 33 Hz, C16, C18, C22, and C24),
131.9 (CH, C4), 131.0 (CH, C10 and C12), 130.6 (CH, C6), 130.2
(m br, CH, C15, C19, C21, and C25), 126.4 (CH, C11), 123.8 (q,
1JCF ) 271 Hz, 4 × CF3), 121.0 (m, CH, C17 and C23), 118.9
t
t
(CH, C5), 117.9 (Cq, C1), 35.0 (Cq, Bu), 29.3 (CH3, Bu). (b)
Preparation of Complex 11a-pyr. To a mixture of [(tmeda)Ni-
(CH3)2] (100 mg, 0.49 mmol) and salicylaldimine 13 (332 mg, 0.49
mmol) in a 25 mL Schlenk flask was added a solution of 0.5 mL
Synthesis of Complex 10a-pyr. (a) Preparation of Salicylal-
dehyde 12. Following the general procedure for the synthesis of